GlaxoSmithKline Pharmaceuticals schedules board meeting to approve Q1 2026 unaudited results

What GlaxoSmithKline Pharmaceuticals announced

GlaxoSmithKline Pharmaceuticals Ltd (BSE: 500660) informed the Bombay Stock Exchange that its Board of Directors will convene on 3 August 2026. The primary purpose of the meeting is to consider, approve and take on record the unaudited financial results for the first quarter ended 30 June 2026.

The notice, filed on 21 July 2026, follows the statutory requirement for listed companies to present quarterly results to shareholders and regulators within a stipulated time frame. No financial figures were disclosed in the intimation; the company will disclose the numbers during the board meeting and subsequently in a formal results release.

Board meeting details

• Date of meeting: 3 August 2026
• Location: GlaxoSmithKline Pharmaceuticals Ltd registered office (exact venue not specified in the filing)
• Agenda: Approval and recording of unaudited Q1 FY2026 results.
• Filing date: 21 July 2026
• Regulatory platform: Bombay Stock Exchange (BSE)

Key facts at a glance

Why this matters for investors

The filing signals that GlaxoSmithKline Pharmaceuticals is complying with its quarterly reporting obligations. While the results are unaudited, the board’s approval is a prerequisite for the company to publish the numbers publicly and for analysts to begin their assessment. Investors should note that unaudited figures may be subject to adjustments once the audit is completed, but the board’s endorsement provides an official record of the company’s performance for the quarter.

Conclusion

GlaxoSmithKline Pharmaceuticals has scheduled a board meeting on 3 August 2026 to approve its unaudited Q1 FY2026 financial results. The company will disclose the detailed numbers after the meeting, and the audited version will follow later in accordance with regulatory timelines.